Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis
James H. Tabibian, Felicity Enders, Mohamad H. Imam, Gururaj Kolar, Keith D. Lindor, Jayant A. Talwalkar.
Annals of Hepatology, 2014, May-June, Vol. 13 No. 3, 2014: 384-389
Abstract
Introduction: Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be as- sociated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC pa- tints.
Material and methods: Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival . . . Please click here to be taken to the full text article
James H. Tabibian, Felicity Enders, Mohamad H. Imam, Gururaj Kolar, Keith D. Lindor, Jayant A. Talwalkar.
Annals of Hepatology, 2014, May-June, Vol. 13 No. 3, 2014: 384-389
Abstract
Introduction: Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be as- sociated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC pa- tints.
Material and methods: Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival . . . Please click here to be taken to the full text article
RSS Feed